Real life experience of apremilast in psoriasis and arthritis psoriatic patients: Preliminary results on metabolic biomarkers

Association between glycated hemoglobin (HbA1c) and the lipid profile in patients with type 2 diabetes mellitus at a tertiary care hospital: a retrospective study

(2019) Sami Hamdan Alzahrani et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-κB signaling pathways

(2018) Faisal Imam et al.   Pharmacological Reports

Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response

(2018) L.M. Sawyer et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice

(2018) J.-T. Maul et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Advances in treating psoriasis in the elderly with small molecule inhibitors

(2017) Abigail Cline et al.   EXPERT OPINION ON PHARMACOTHERAPY

Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis

(2017) Yu Woo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Psoriasis and comorbid diseases

(2017) Junko Takeshita et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis

(2017) P. Gisondi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Real-World Experience With Apremilast in Treating Psoriasis

(2016) Julia N. Mayba et al.   JOURNAL OF CUTANEOUS MEDICINE AND SURGERY

Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders

(2016) C. Wu et al.   Obesity Reviews

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast

(2015) Melinda Gooderham et al.   BIODRUGS

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors

(2015) Miguel Perez-Aso et al.   ARTHRITIS RESEARCH & THERAPY

Phosphodiesterase 4-targeted treatments for autoimmune diseases

(2013) Neal Kumar et al.   BMC Medicine

Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A?systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis

(2011) Amanda Robinson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.

(2010) K Abuabara et al.   BRITISH JOURNAL OF DERMATOLOGY

Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany

(2008) M. Augustin et al.   DERMATOLOGY